Investigating calcium signaling in heart disease
Crosstalk Ca2+ Signaling between Ryanodine Receptors Type 1 and 2 in the Pathogenesis of Cardiac Hypertrophy and Heart Failure
This study is looking at how certain signals in heart cells can affect heart health, especially in people with heart failure, by using mice to understand how these signals change when the heart is under stress, which could help find new treatments for heart problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11052467 on NIH RePORTER |
What this research studies
This research explores how calcium signaling between specific receptors in heart cells contributes to heart failure and cardiac hypertrophy. By examining the role of ryanodine receptors in energy regulation within heart cells, the study aims to uncover the molecular mechanisms that lead to heart dysfunction. The approach involves using mouse models to analyze changes in calcium levels and energy production in heart cells under stress conditions. Patients may benefit from insights gained that could lead to new treatments for heart conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with heart failure or those at risk of developing cardiac hypertrophy.
Not a fit: Patients with non-cardiac related conditions or those without heart disease may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic strategies for treating heart failure and improving heart function.
How similar studies have performed: Previous research has shown promising results in understanding calcium signaling in heart disease, indicating that this approach has potential for success.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Sheu, Shey-Shing — Thomas Jefferson University
- Study coordinator: Sheu, Shey-Shing
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.